{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"Multizentrische, länderübergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie","eudractNumber":null,"id":9352,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-10T10:14:43+02:00","shortTitle":"NERLYFE-Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Deutsches Register neuroendokrine Tumore","eudractNumber":null,"id":8571,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2022-07-13T14:12:52+02:00","shortTitle":"NET-Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Registry of the NHL-BFM study group for all subtypes of\nNon-Hodgkin                                 lymphoma diagnosed in\nchildren and adolescents Gesellschaft für Pädiatrische\nOnkologie und Hämatologie (GPOH) 

","eudractNumber":null,"id":11279,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-02-24T12:37:35+01:00","shortTitle":"NHL-BFM Registry V.2024.1","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial","eudractNumber":"2018-005027-16","id":6809,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"1p/19q-Kodeletion","id":"mt_261"}],"nctNumber":"NCT05331521","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-06-17T11:24:58+02:00","shortTitle":"NOA-18 / IMPROVE CODEL: the NOA-18 trial","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Dieses Single Patient\nRequest (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access\nProgram (I-EAP) soll einen frühzeitigen Zugang zu\nNiraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit\nPrednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen\nungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein\nmetastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben\nund bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn\nund/oder somatisch) positiv sind.","eudractNumber":null,"id":7946,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-14T16:19:57+02:00","shortTitle":"NPP 67652000MPC4001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","eudractNumber":null,"id":4357,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05934032","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-01-01T12:00:40+01:00","shortTitle":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Preoperative radiotherapy versus postoperative radiotherapy after neoadjuuvant chemotherapy (\"NeoRad\") in high-risk breast cancer: a prospective, randomized, international, multicenter Phase III trial","eudractNumber":null,"id":10183,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04261244","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-02T13:46:11+02:00","shortTitle":"NeoRad","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"Netzwerk Onkologie (NO) - Therapiebegleitende Darstellung des Versorgungsalltages in der integrativen Onkologie

DRKS: DRKS00013335

Retrospektiv
","eudractNumber":null,"id":12273,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-22T08:21:56+02:00","shortTitle":"Netzwerk Onkologie (NO)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"2- and 5-year neuropsychological follow-up of young\nchildren with medulloblastoma, CNS-PNET and ependymoma treated within the prospective\nmulticenter trial HIT 2000 SKK

Geplante Laufzeit: 01.07.2013 - 31.03.2017
","eudractNumber":null,"id":964,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2013-07-01T13:26:27+02:00","shortTitle":"Neuropsychological diagnostics in HIT 2000 SKK","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"}],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}